Moderna (MRNA) Net Income towards Common Stockholders Growth (3y) (2020 - 2026)
Powered by 
Analysis
Moderna (MRNA) Net Income towards Common Stockholders Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 19.87% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -129.59% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 6.30% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 10.23% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 17.25% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 91.31% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 37.44% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -45.23% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | 62.15% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.25% |
| Mar 31, 2026 | -166.84% |
| Dec 31, 2025 | -36.87% |
| Sep 30, 2025 | -29.90% |
| Jun 30, 2025 | -33.43% |
| Mar 31, 2025 | -31.34% |
| Dec 31, 2024 | -30.65% |
| Sep 30, 2024 | -84.26% |
| Jun 30, 2024 | -34.99% |
| Mar 31, 2024 | -43.62% |
| Dec 31, 2023 | 40.86% |
| Sep 30, 2023 | -149.76% |
| Jun 30, 2023 | -127.63% |
| Mar 31, 2023 | 38.16% |
| Dec 31, 2022 | 140.44% |
| Sep 30, 2022 | 118.74% |
| Jun 30, 2022 | 163.37% |
| Mar 31, 2022 | 209.22% |
| Dec 31, 2021 | 229.53% |
| Sep 30, 2021 | 241.86% |